Stock Events

Stock Events

Hepion Pharmaceuticals 

€0
0
+€0+0% Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

12MayExpected
Q1 2025
Next
-89.69
-89.35
-89.02
-88.69
Expected EPS
N/A
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 3360.MU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Gilead Sciences
GILD
Mkt Cap173.41B
Gilead Sciences is a leading biopharmaceutical company that develops and markets drugs for life-threatening illnesses including liver disease, a key area of focus for Hepion Pharmaceuticals.
Vertex Pharmaceuticals
VRTX
Mkt Cap111.43B
Vertex Pharmaceuticals is involved in creating treatments for serious diseases, including liver diseases, which puts it in direct competition with Hepion Pharmaceuticals' efforts in NASH and liver-related treatments.
Madrigal Pharmaceuticals
MDGL
Mkt Cap12.55B
Madrigal Pharmaceuticals focuses on the development of novel therapies for cardiovascular, metabolic, and liver diseases, including NASH, making it a competitor in Hepion's market space.
Viking Therapeutics
VKTX
Mkt Cap4.02B
Viking Therapeutics is working on treatments for metabolic and endocrine disorders, including NASH, positioning it as a competitor to Hepion Pharmaceuticals in the NASH treatment market.
Galmed Pharmaceuticals
GLMD
Mkt Cap3.55M
Galmed Pharmaceuticals is engaged in the development of oral therapies for the treatment of liver diseases, including NASH, competing with Hepion Pharmaceuticals in the liver disease therapeutic area.
Agios Pharmaceuticals
AGIO
Mkt Cap2.06B
Agios Pharmaceuticals focuses on cellular metabolism and rare genetic diseases, including metabolic and liver-related diseases, making it a competitor in the broader market for liver disease treatments.
Enanta Pharmaceuticals
ENTA
Mkt Cap384.51M
Enanta Pharmaceuticals is focused on creating treatments for liver diseases and respiratory infections, with a significant focus on liver diseases, making it a competitor to Hepion.

About

Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It is involved in developing CRV431, a cyclophilin inhibitor that is in Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.
Show more...
CEO
Dr. Robert T. Foster B.Sc., BSc (Pharm), Pharm.D., Ph.D.
Employees
13
Country
United States
ISIN
US4268974015

Listings

STU
DE
3360.STU
MU
DE
3360.MU
OTC Link
US
HEPA
OTC Link
US
CTRVP

0 Comments

Share your thoughts

FAQ

What is Hepion Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Hepion Pharmaceuticals stocks are traded under the ticker 3360.MU.
When is the next Hepion Pharmaceuticals earnings date?▼
Hepion Pharmaceuticals is going to release the next earnings report on May 12, 2026.
How many employees does Hepion Pharmaceuticals have?▼
As of April 13, 2026, the company has 13 employees.
In which sector is Hepion Pharmaceuticals located?▼
Hepion Pharmaceuticals operates in the Health & Wellness sector.
When did Hepion Pharmaceuticals complete a stock split?▼
Hepion Pharmaceuticals has not had any recent stock splits.
Where is Hepion Pharmaceuticals headquartered?▼
Hepion Pharmaceuticals is headquartered in Edison, United States.